8-K: Bioxytran Amends Preferred Stock, Grants CEO Equity

Bioxytran, Inc. modified its Convertible Preferred Stock conversion terms and awarded 6 million shares of Preferred Stock to CEO David Platt for commercial and capital funding efforts.

Summary

• An amendment to the Certificate of Designation of Convertible Preferred Stock was filed with the Nevada Secretary of State on February 18, 2026, becoming effective upon filing.
• The amendment modifies the conversion provisions of the company's Preferred Stock, requiring approval from both the Board of Directors and the holders of a majority of the outstanding shares of Preferred Stock voting as a single class for any conversion into Common Stock.
• This amendment was adopted to ensure appropriate corporate and preferred shareholder approvals for any conversion of Convertible Preferred Stock.
• The Board of Directors approved a performance-based equity award of 6,000,000 shares of Convertible Preferred Stock to David Platt, the company's Chief Executive Officer.
• The award recognizes Dr. Platt's role in executing the company's first commercial distribution agreement and advancing capital funding initiatives.
• The Board approved the award to align executive incentives with the company's commercialization and capital formation objectives.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns executive incentives with strategic goals and enhances corporate governance, despite the potential for future dilution from the equity award.

Positives

• CEO David Platt received a performance-based equity award recognizing his success in executing the company's first commercial distribution agreement.
• The CEO was also recognized for advancing capital funding initiatives, indicating progress in securing financial resources.
• The equity award aligns executive incentives directly with the company's commercialization and capital formation objectives, potentially driving future growth.
• New conversion provisions for preferred stock enhance corporate governance by requiring dual approvals (Board and preferred shareholders), providing more control over potential dilution.

Negatives

• The grant of 6,000,000 shares of Convertible Preferred Stock to the CEO introduces potential future dilution for common shareholders if these shares are converted.

Risks

• Future conversion of the 6,000,000 shares of Convertible Preferred Stock granted to the CEO could dilute the ownership percentage of existing common shareholders.
• The requirement for preferred shareholder approval for conversion, while enhancing governance, could introduce complexities or potential conflicts of interest in future capital structure decisions.

Future Outlook

The company aims to continue its commercialization efforts and advance capital funding initiatives, with executive incentives now aligned with these strategic objectives.

Management Comments

• "The amendment was adopted to ensure that any conversion of the Company's Convertible Preferred Stock is subject to appropriate corporate and preferred shareholder approvals."
• "The Board approved the award to align executive incentives with the Company's commercialization and capital formation objectives."

Industry Context

StockSavvy.ai notes that performance-based equity awards are a common mechanism in the biotechnology and emerging growth sectors to incentivize leadership, particularly for achieving critical milestones like securing commercial distribution agreements and advancing capital funding. The modification of preferred stock conversion rights is also a typical corporate governance adjustment, often made to manage capital structure and shareholder control.

Comparison to Industry Standards

• The grant of 6 million shares of Convertible Preferred Stock to a CEO is a substantial equity award, common in early-stage biotech companies where executive compensation is heavily weighted towards equity to conserve cash and align long-term interests.
• The dual approval requirement for preferred stock conversion (Board and majority of preferred shareholders) is a robust governance measure, potentially more stringent than some industry peers, aiming to protect preferred shareholder interests and manage common stock dilution.

Corporate Governance

Related Party Transactions

• Grant of 6,000,000 shares of Convertible Preferred Stock to CEO David Platt as a performance award.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock due to preferred stock conversion, but improved governance over such conversions. Alignment of CEO incentives with company growth.
• CEO (David Platt): Significant equity award for performance, aligning personal financial interests with company success.

Next Steps

• Continued execution of commercial distribution agreements.
• Advancement of capital funding initiatives.
• Ongoing commercialization efforts.

Key Dates

Keywords

Bioxytran, BIXT, SEC Filing, 8-K, Convertible Preferred Stock, Equity Award, CEO Compensation, Corporate Governance, Stock Dilution, Capital Funding, Commercial Distribution